Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
暂无分享,去创建一个
Silvia Benvenuti | M. Moroni | A. Bardelli | F. Di Nicolantonio | S. Benvenuti | S. Veronese | C. Zanon | A. Sartore-Bianchi | S. Siena | Federica Di Nicolantonio | Alberto Bardelli | Andrea Sartore-Bianchi | Salvatore Siena | Silvio Veronese | Carlo Zanon | Mauro Moroni
[1] D. Lynch,et al. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. , 2002, Seminars in oncology.
[2] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Giovanni Parmigiani,et al. Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.
[4] K. Kawakami,et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status , 2006, Molecular Cancer.
[5] J. Lyssikatos,et al. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. , 2005, Current topics in medicinal chemistry.
[6] G. Qiao,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .
[7] K. Venkatasubbarao,et al. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. , 2005, Cancer research.
[8] G. Nicolson,et al. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. , 1996, Cancer research.
[9] D. Shalloway,et al. Cell cycle-dependent activation of Ras , 1996, Current Biology.
[10] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[11] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[12] J. Meyerhardt,et al. Systemic therapy for colorectal cancer. , 2005, The New England journal of medicine.
[13] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[14] J. Baselga,et al. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[16] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[17] K. Kinzler,et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.
[18] S Rozen,et al. Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.
[19] S. Leung,et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs , 2005, Journal of Clinical Pathology.
[20] B. Wiens,et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Z. Hua. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .